Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FT819,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fate Therapeutics Treats First Lupus Patient in Phase 1 Study of FT819 CAR T-Cell Program
Details : FT819 is the first-ever, off-the-shelf, iPSC-derived CAR T-cell therapy, which is currently being evaluated for the treatment of moderate to severe active systemic lupus erythematosus.
Brand Name : FT819
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 09, 2024
Lead Product(s) : FT819,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : FT522,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fate Presents FT522 Preclinical Data for Autoimmune Diseases At ASGCT
Details : FT522 is an iPSC-derived CAR NK cell targeting CD19 with ADR technology, under evaluation for relapsed/refractory B-cell lymphoma.
Brand Name : FT522
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
May 03, 2024
Lead Product(s) : FT522,Rituximab,Cyclophosphamide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fate Therapeutics Prices $100 Million Underwritten Offering and Private Placement
Details : The Company plans to use net proceeds to fund clinical trials and nonclinical studies of its candidates, including FT576, an investigational CAR NK cell cancer immunotherapy.
Brand Name : FT576
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 19, 2024
Fate Therapeutics Initiates Phase 1 Trial for FT825 / ONO-8250 in Advanced Solid Tumors
Details : ONO-8250 (FT825) is a multiplexed-engineered CAR T-cell candidate targeting HER2, under Phase 1 trials for HER2-expressing advanced solid tumors.
Brand Name : ONO-8250
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
January 08, 2024
Lead Product(s) : Allogenic CAR NK Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Janssen
Deal Size : $3,100.0 million
Deal Type : Termination
Details : FT576 (CAR NK cells) is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master iPSC line. FT576 incorporates a proprietary CAR that targets BCMA, a novel high-affinity 158V and non-cleavable CD16 (hnCD16) F...
Brand Name : FT576
Molecule Type : Cell and Gene therapy
Upfront Cash : $100.0 million
January 05, 2023
Lead Product(s) : Allogenic CAR NK Cell,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Janssen
Deal Size : $3,100.0 million
Deal Type : Termination
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FT819 is an investigational, universal, off-the-shelf, T-cell receptor (TCR)-less CD19 chimeric antigen receptor (CAR) T-cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line.
Brand Name : FT819
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
December 10, 2022
Lead Product(s) : FT819,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ONO-8250
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the Collaboration and Option Agreement, the parties will jointly develop and commercialize FT825 (ONO-8250) in the U.S. and Europe, and ONO maintains exclusive development and commercialization rights for FT825 (ONO-8250) in the rest o...
Brand Name : FT825
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 07, 2022
Lead Product(s) : ONO-8250
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : FT819, an off-the-shelf CAR T-cell cancer immunotherapy derived from a clonal engineered master iPSC line with a novel 1XX CAR targeting CD19 inserted into the T-cell receptor alpha constant (TRAC) locus and edited for elimination of T-cell receptor (TCR...
Brand Name : FT819
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : GTB-3650,CAR NK Cell Therapy
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : GT Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Preclinical data to be presented demonstrate that iPSC-derived, MICA/B-targeted CAR NK cells induced potent activity against AML cell line HL60, and further enhancement of activity was achieved in combination with GTB-3650 through antibody-dependent cell...
Brand Name : GTB-3650
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 03, 2022
Lead Product(s) : GTB-3650,CAR NK Cell Therapy
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : GT Biopharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : FT536,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : FT536 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy derived from a clonal master engineered iPSC line. FT536 incorporates a proprietary CAR that targets the α3 domain of MICA and MICB.
Brand Name : FT536
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
October 05, 2022
Lead Product(s) : FT536,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?